cardio pharm Flashcards
cats should not receive lidocaine IV (t/f)
true
acetylcholine is the neurotransmitter that is secreted by the parasympathetic nervous system (t/f)
true
lidocaine is an example of an
sodium channel blocker
atenolol is an example of a
beta blocker
what are the three catecholamines
epinephrine, dopamine, norepepinephrine
which of the following can be added to lidocaine to cause vasoconstriction when used as a local anesthetic, but never given IV:
lasix, propofol, epinephrine
epinephrine
what is the drug of choice when treating ventricular tachycardia
lidocaine
vasoconstriction will cause hypotension (t/f)
false
positive inotropic drugs:
increase the force of cardiac contractions
which of the following antiarrhythmic drugs can be used when treating animals with ARVC
class 3 - potassium channel blockers
what happens when Beta-1 adrenergic receptors are stimulated
increased HR, increase cardiac contractions and increased force
in regards to the cardiovascular system, the parasympathetic nervous system causes what
slows HR, dilate vessels to GI tract, increase blood flow to kidneys, decrease size of bronchioles, miosis, little peripheral arteries
when talking about the parasympathetic nervous system, what neurotransmitter is stimulated
cholinergic
what is the selective beta-blocker that is commonly used in cats with HCM
atenolol
2 ACE-inhibitors
enalapril and benazepril
why would you avoid using pimobendan in a pt with HCM
heart is already enlarged, drug will cause increased contractability of the heart, more stress on the heart
what effect do inotropic drugs have on the cardiovascular system
affect the strength of contraction of a weakened heart, positive increase, negative decrease
what effect do inodilator drugs have on the CV system
increases the CO without increasing the workload of the heart
why is it good to start a patient in heart failure on vasodilators
reduce vessel constriction, reduces the amount of work the heart has to do
which class of antiarrhythmics is most commonly used in Boxers with ARVC disease
potassium channel blockers